Coagulation

Sepsis and Non-Infectious Systemic Inflammation: From Biology to Critical Care

Volumn , Issue , 2009, Pages 251-278

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticoagulant pathway; Coagulation abnormality; Disseminated intravascular coagulation (DIC); Fibrinolysis; Thrombocytopenia; Tissue factor

Indexed keywords

EID: 84861396896     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626151.ch11     Document Type: Chapter

References (148)

1. Levi, M., ten Cate, H., Van Der Poll, T. and van Deventer, S.J. (1993) Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA, 270, 975-9.
2. Levi, M. and ten Cate, H. (1999) Disseminated intravascular coagulation. N. Engl. J. Med., 341, 586-92.
3. Colman, R.W., Robboy, S.J. and Minna, J.D. (1979) Disseminated intravascular coagulation: a reappraisal. Annu. Rev. Med., 30, 359-74.
4. Levi, M., van Gorp, E. and ten Cate, H. (2002) Disseminated Intravascular Coagulation, in Blood: Pinciples and Practice of Hematology (eds R.I.Handin, S.E. Lux and T.P. Stossel), J.B.Lippincott, Philadelphia.
5. Levi, M. and Marder, V.J. (2006) Coagulation abnormalities in sepsis, in Hemostasis and Thrombosis: Basic Principles and Clinical Practice (eds R.W. Colman, V.J. Marder, A.W. Clowes, J.N. George and S.Z. Goldhaber), Lippincott William and Wilkins, Philadelphia, pp. 1601-13.
6. Miller, D.L., Welty-Wolf, K., Carraway, M.S., Ezban, M., Ghio, A., Suliman, H. and Piantadosi, C.A. (2002) Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am. J. Respir. Cell. Mol. Biol., 26, 650-8.
7. Levi, M., ten Cate, H. and Van Der Poll, T. (1999) Disseminated intravascular coagulation: State of the art. Thromb. Haemost., 82, 695-705.
8. Ratnoff, O.D. and Nebehay, W.G. (1962) Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. Ann. Intern. Med., 56, 627.
9. Levi, M., Keller, T.T., van Gorp, E. and ten Cate, H. (2003) Infection and inflammation and the coagulation system. Cardiovasc. Res., 60, 26-39.
10. Robboy, S.J., Major, M.C., Colman, R.W. and Minna, J.D. (1972) Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum. Pathol., 3, 327-43.
11. Shimamura, K., Oka, K., Nakazawa, M. and Kojima, M. (1983) Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch. Pathol. Lab. Med., 107, 543-7.
12. Coalson, J.J. Pathology of Sepsis, Septic Shock, and Multiple Organ Failure. Perspective on Sepsis and Septic Shock, Society of Critical Care Medicine, Fullerton, CA, (1986) pp. 27-59.
13. Creasey, A.A., Chang, A.C., Feigen, L., Wun, T.C., Taylor, F.B.J. and Hinshaw, L.B. (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest., 91, 2850-6.
14. Kessler, C.M., Tang, Z., Jacobs, H.M. and Szymanski, L.M. (1997) The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood, 89, 4393-401.
15. Taylor, F.B.J., Chang, A., Ruf, W., Morrissey, J.H., Hinshaw, L., Catlett, R., et al. (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock, 33, 127-34.
16. Taylor, F.B. J., Chang, A., Esmon, C.T., D'Angelo, A., Vigano-D'Angelo, S. and Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest., 79, 918-25.
17. Welty-Wolf, K.E., Carraway, M.S., Miller, D.L., Ortel, T.L., Ezban, M., Ghio, A.J., et al. (2001) Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am. J. Respir. Crit. Care Med., 164, 1988-96.
18. Fourrier, F., Chopin, C., Goudemand, J., Hendrycx, S., Caron, C., Rime, A., et al. (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies see comments]. Chest, 101, 816-23.
19. Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B.R., Brandt, J.T., et al. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost., 2, 1924-33.
20. Vanderschueren, S., De Weerdt, A., Malbrain, M., Vankersschaever, D., Frans, E., Wilmer, A. and Bobbaers, H. (2000) Thrombocytopenia and prognosis in intensive care. Crit. Care Med., 28, 1871-6.
21. Strauss, R., Wehler, M., Mehler, K., Kreutzer, D., Koebnick, C. and Hahn, E.G. (2002) Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit. Care Med., 30, 1765-71.
22. Oppenheim-Eden, A., Glantz, L., Eidelman, L.A. and Sprung, C.L. (1999) Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med., 25, 63-7.
23. Stephan, F., Hollande, J., Richard, O., Cheffi, A., Maier-Redelsperger, M. and Flahault, A. (1999) Thrombocytopenia in a surgical ICU. Chest, 115, 1363-70.
24. Akca, S., Haji Michael, P., de Medonca, A., Suter, P.M., Levi, M. and Vincent, J.L. (2002) The time course of platelet counts in critically ill patients. Crit. Care Med., 30, 753-6.
25. Chakraverty, R., Davidson, S., Peggs, K., Stross, P., Garrard, C. and Littlewood, T.J. (1996) The incidence and cause of coagulopathies in an intensive care population. Br. J. Haematol., 93, 460-3.
26. MacLeod, J.B., Lynn, M., McKenney, M.G., Cohn, S.M. and Murtha, M. (2003) Early coagulopathy predicts mortality in trauma. J. Trauma., 55, 39-44.
27. Wheeler, A.P. and Bernard, G.R. (1999) Treating patients with severe sepsis. N. Engl. J. Med., 340, 207-14.
28. Levi, M., de Jonge, E. and van Der, P.T. (2003) Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis., 16, 43-7.
29. Baughman, R.P., Lower, E.E., Flessa, H.C. and Tollerud, D.J. (1993) Thrombocytopenia in the intensive care unit. Chest, 104, 1243-7.
30. Mavrommatis, A.C., Theodoridis, T., Orfanidou, A., Roussos, C., Christopoulou-Kokkinou, V. and Zakynthinos, S. (2000) Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit. Care Med., 28, 451-7.
31. Folman, C.C., Linthorst, G.E., van Mourik, J., van Willigen, G., de Jonge, E., Levi, M., et al. (2000) Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb. Haemost., 83, 923-30.
32. Francois, B., Trimoreau, F., Vignon, P., Fixe, P., Praloran, V. and Gastinne, H. (1997) Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am. J. Med., 103, 114-20.
33. Warkentin, T.E., Aird, W.C. and Rand, J.H. (2003) Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology 2003. (Am. Soc. Hematol. Educ. Program), 497-519.
34. Shorr, A.F., Thomas, S.J., Alkins, S.A., Fitzpatrick, T.M. and Ling, G.S. (2002) D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest, 121, 1262-8.
35. Owings, J.T., Gosselin, R.C., Anderson, J.T., Battistella, F.D., Bagley, M. and Larkin, E.C. (2001) Practical utility of the D-dimer assay for excluding thromboembolism in severely injured trauma patients. J. Trauma., 51, 425-9.
36. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsi. N. Engl. J. Med., Mar 8, 344(10), 344, 699-709.
37. Gando, S., Nanzaki, S., Sasaki, S. and Kemmotsu, O. (1998) Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb. Haemost., 79, 1111-5.
38. Levi, M., Van Der Poll, T., ten Cate, H. and van Deventer, S.J. (1997) The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur. J. Clin. Invest., 27, 3-9.
39. Levi, M., Van Der Poll, T. and Buller, H.R. (2004) The bidirectional relationshiop between coagulation and inflammation. Circulation, 109, 2698-704.
40. Aird, W.C. (2001) Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit. Care Med., 29, S28-S34.
41. Levi, M., ten Cate, H., Bauer, K.A., Van Der Poll, T., Edgington, T.S., Buller, H.R., et al. (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest., 93, 114-20.
42. Biemond, B.J., Levi, M., ten Cate, H., Soule, H.R., Morris, L.D., Foster, D.L., et al. (1995) Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb. Haemost., 73, 223-30.
43. van Deventer, S.J., Buller, H.R., ten Cate, J.W., Aarden, L.A., Hack, C.E. and Sturk, A. (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood, 76, 2520-6.
44. Van Der Poll, T., Buller, H.R., ten Cate, H., Wortel, C.H., Bauer, K.A., van Deventer, S.J., et al. (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med., 322, 1622-7.
45. Ruf, W. and Edgington, T.S. (1994) Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB. J., 8, 385-90.
46. Osterud, B. and Flaegstad, T. (1983) Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost., 49, 5-7.
47. Franco, R.F., de Jonge, E., Dekkers, P.E., Timmerman, J.J., Spek, C.A., et al. (2000) The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood, 96, 554-9.
48. Giesen, P.L., Rauch, U., Bohrmann, B., Kling, D., Roque, M., Fallon, J.T., et al. (1999) Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. USA., 96, 2311-5.
49. Osterud, B., Rao, L.V. and Olsen, J.O. (2000) Induction of tissue factor expression in whole blood-lack of evidence for the presence of tissue factor expression on granulocytes. Thromb. Haemost., 83, 861-7.
50. Rauch, U., Bonderman, D., Bohrmann, B., Badimon, J.J., Himber, J., Riederer, M.A. and Nemerson, Y. (2000) Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood, 96, 170-5.
51. Vary, T.C. and Kimball, S.R. (1992) Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am. J. Physiol., 262, C445-C452.
52. Seitz, R., Wolf, M., Egbring, R. and Havemann, K. (1989) The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur. J. Haematol., 43, 22-8.
53. Opal, S.M., Kessler, C.M., Roemisch, J. and Knaub, S. (2002) Antithrombin, heparin, and heparan sulfate. Crit. Care Med., 30, S325-S331.
54. Mesters, R.M., Mannucci, P.M., Coppola, R., Keller, T., Ostermann, H. and Kienast, J. (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients (see comments). Blood, 88, 881-6.
55. Esmon, C.T. (2002) New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J. Exp. Med., 196, 561-4.
56. Zushi, M., Gomi, K., Yamamoto, S., Maruyama, I., Hayashi, T. and Suzuki, K. (1989) The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J. Biol. Chem., 264, 10351-3.
57. Bajzar, L., Morser, J. and Nesheim, M. (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J. Biol. Chem., 271, 16603-8.
58. Taylor, F.B. Jr., PeerG.T., Lockhart M.S., Ferrell G. and Esmon C.T. (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood, 97, 1685-8.
59. Eckle, I., Seitz, R., Egbring, R., Kolb, G. and Havemann, K. (1991) Protein C degradation in vitro by neutrophil elastase. Biol. Chem. Hoppe. Seyler., 372, 1007-13.
60. Nawroth, P.P. and Stern, D.M. (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163, 740-5.
61. Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med., 345(6), 408-16.
62. Garcia de Frutos, P., Alim, R.I., Hardig, Y., Zoller, B. and Dahlback, B. (1994) Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood, 84, 815-22.
63. Taylor, F., Chang, A., Ferrell, G., Mather, T., Catlett, R., Blick, K., et al. (1991) C4b-binding protein exacerbates the host response to Escherichia coli. Blood, 78, 357-63.
64. Taylor, F.BJ., Dahlback, B., Chang, A.C., Lockhart, M.S., Hatanaka, K., Peer, G. and Esmon, C.T. (1995) Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood, 86, 2642-52.
65. Levi, M., Dorffler-Melly, J., Reitsma, P.H., Buller, H.R., Florquin, S., Van Der Poll, T. and Carmeliet, P. (2003) Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood, 101, 4823-7.
66. Broze, G.J., Jr., Girard T.J. and Novotny W.F. (1990) Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry, 29, 7539-46.
67. de Jonge, E., Dekkers, P.E., Creasey, A.A., Hack, C.E., Paulson, S.K., Karim, A., et al. (2000) Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activtion without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood, 95, 1124-9.
68. Gando, S., Kameue, T., Morimoto, Y., Matsuda, M., Hayakawa, M. and Kemmotsu, O. (2002) Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit. Care Med., 30, 1729-34.
69. Levi, M. (2002) The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit. Care Med., 30, 1914-5.
70. Van Der Poll, T., Levi, M., Buller, H.R., van Deventer, S., de Boer, J., Hack, C.E., et al. (1991) Fibrinolytic response to tumor necrosis factor in healthy subjects. J. Exp. Med., 174, 729-32.
71. Biemond, B.J., Levi, M., ten Cate, H., Van Der Poll, T., Buller, H.R., Hack, C.E. and ten Cate, J.W. (1995) Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin. Sci. (Colch.), 88, 587-94.
72. Yamamoto, K. and Loskutoff, D.J. (1996) Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J. Clin. Invest., 97, 2440-51.
73. Pinsky, D.J., Liao, H., Lawson, C.A., Yan, S.F., Chen, J., Carmeliet, P., et al. (1998) Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J. Clin. Invest., 102, 919-28.
74. Hermans, P.W., Hibberd, M.L., Booy, R., Daramola, O., Hazelzet, J.A., de, G.R. and Levin, M. (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet., 354, 556-60.
75. Westendorp, R.G., Hottenga, J.J. and Slagboom, P.E. (1999) Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet., 354, 561-3.
76. Hack, C.E., Aarden, L.A. and Thijs, L.G. (1997) Role of cytokines in sepsis. Adv. Immunol., 66, 101-95.
77. Bauer, K.A., ten Cate, H., Barzegar, S., Spriggs, D.R., Sherman, M.L. and Rosenberg, R.D. (1989) Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood, 74, 165-72.
78. Van Der Poll, T., Levi, M., van Deventer, S.J., ten Cate, H., Haagmans, B.L., Biemond, B.J., et al. (1994) Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood, 83, 446-51.
79. Van Der Poll, T., Coyle, S.M., Levi, M., Jansen, P.M., Dentener, M., Barbosa, K., et al. (1997) Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood, 89, 3727-34.
80. Hinshaw, L.B., Tekamp-Olson, P., Chang, A.C., Lee, P.A., Taylor, F.B., Jr., Murray, C.K., et al. (1990) Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ. Shock, 30, 279-92.
81. Abraham, E., Wunderink, R., Silverman, H., Perl, T.M., Nasraway, S., Levy, H., et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA, 273, 934-41.
82. Van Der Poll, T., Levi, M., Hack, C.E., ten Cate, H., van Deventer, S.J., Eerenberg, A.J., et al. (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med., 179, 1253-9.
83. Stouthard, J.M., Levi, M., Hack, C.E., Veenhof, C.H., Romijn, H.A., Sauerwein, H.P. and Van Der Poll, T. (1996) Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost., 76, 738-42.
84. Fischer, E., Marano, M.A., van Zee, K.J., Rock, C.S., Hawes, A.S., Thompson, W.A., et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest., 89, 1551-7.
85. Jansen, P.M., Boermeester, M.A., Fischer, E., de, J.I., van, dP., Moldawer, L.L., et al. (1995) Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood, 86, 1027-34.
86. Boermeester, M.A., van, L.P., Coyle, S.M., Wolbink, G.J., Hack, C.E. and Lowry, S.F. (1995) Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch. Surg., 130, 739-48.
87. Pajkrt, D., van, dP., Levi, M., Cutler, D.L., Affrime, M.B., van, dE., et al. (1997) Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood, 89, 2701-5.
88. Mileno, M.D., Margolis, N.H., Clark, B.D., Dinarello, C.A., Burke, J.F. and Gelfand, J.A. (1995) Coagulation of whole blood stimulates interleukin-1 beta gene expression. J. Infect. Dis., 172, 308-11.
89. Jones, A. and Geczy, C.L. (1990) Thrombin and factor Xa enhance the production of interleukin-1. Immunology., 71, 236-41.
90. Johnson, K., Choi, Y., DeGroot, E., Samuels, I., Creasey, A. and Aarden, L. (1998) Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol., 160, 5130-5.
91. Sower, L.E., Froelich, C.J., Carney, D.H., Fenton, J.W. and Klimpel, G.R. (1995) Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J. Immunol., 155, 895-901.
92. Van Der Poll, T., de Jonge, E. and Levi, M. (2001) Regulatory role of cytokines in disseminated intravascular coagulation. Semin. Thromb. Hemost., 27, 639-51.
93. Coughlin, S.R. (2000) Thrombin signalling and protease-activated receptors. Nature, 407, 258-64.
94. de Jonge, E., Friederich, P.W., Levi, M. and Van Der Poll, T. (2003) Activation of coagulation by administration of recombinant factor VIIa elcicits interleukin-6 and interleukin-8 release in healthy humen subjects. Clin. Diagn. Lab. Immunol., 10, 495-7.
95. Kaneider, N.C., Forster, E., Mosheimer, B., Sturn, D.H. and Wiedermann, C.J. (2003) Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb. Haemost., 90, 1150-7.
96. Okajima, K. (2001) Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev., 184, 258-74.
97. Grey, S.T., Tsuchida, A., Hau, H., Orthner, C.L., Salem, H.H. and Hancock, W.W. (1994) Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J. Immunol., 153, 3664-72.
98. Yuksel, M., Okajima, K., Uchiba, M., Horiuchi, S. and Okabe, H. (2002) Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb. Haemost., 88, 267-73.
99. Murakami, K., Okajima, K., Uchiba, M., Johno, M., Nakagaki, T., Okabe, H. and Takatsuki, K. (1996) Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood, 87, 642-7.
100. Taylor, F.B., Jr. (1994) Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. (Review; 13 refs). Prog. Clin. Biol. Res., 388, 175-94.
101. Taylor, F.BJ., Stearns-Kurosawa, D.J., Kurosawa, S., Ferrell, G., Chang, A.C., Laszik, Z., et al. (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood, 95, 1680-6.
102. White, B., Schmidt, M., Murphy, C., Livingstone, W., O'Toole, D., Lawler, M., et al. (2000) Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br. J. Haematol., 110(1), 130-4.
103. Hancock, W.W., Grey, S.T., Hau, L., Akalin, E., Orthner, C., Sayegh, M.H. and Salem, H.H. (1995) Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation, 60, 1525-32.
104. Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. and Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 296, 1880-2.
105. Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen, E.D., et al. (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med.
106. Mosnier, L.O. and Griffin, J.H. (2003) Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem. J., 373, 65-70.
107. Neame, P.B., Kelton, J.G., Walker, I.R., Stewart, I.O., Nossel, H.L. and Hirsh, J. (1980) Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood, 56, 88-92.
108. Levi, M., de Jonge, E. and Meijers, J. (2002) The diagnosis of disseminated intravascular coagulation. Blood Rev., 16, 217-23.
109. Dempfle, C.E., Pfitzner, S.A., Dollman, M., Huck, K., Stehle, G. and Heene, D.L. (1995) Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb. Haemost., 74, 673-9.
110. Bredbacka, S., Blomback, M. and Wiman, B. (1994) Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am. J. Hematol., 46, 289-94.
111. Okajima, K., Uchiba, M., Murakami, K., Okabe, H. and Takatsuki, K. (1996) Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation. Am. J. Hematol., 51, 186-91.
112. McCarron, B.I., Marder, V.J., Kanouse, J.J. and Francis, C.W. (1999) A soluble fibrin standard: comparable dose-response with immunologic and functional assays. Thromb. Haemost., 82, 145-8.
113. Dempfle, C.E. (1999) The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. (Review; 147 refs). Thromb. Haemost., 82, 673-83.
114. Horan, J.T. and Francis, C.W. (2001) Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin. Thromb. Hemost., 27(6), 657-66.
115. McCarron, B.I., Marder, V.J. and Francis, C.W. (1999) Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb. Haemost., 82, 1722-9.
116. Carr, J.M., McKinney, M. and McDonagh, J. (1989) Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am. J. Clin. Pathol., 91, 280-7.
117. Boisclair, M.D., Ireland, H. and Lane, D.A. (1990) Assessment of hypercoagulable states by measurement of activation fragments and peptides. (Review; 113 refs). Blood Rev., 4, 25-40.
118. Prisco, D., Paniccia, R., Bonechi, F., Francalanci, I., Abbate, R. and Gensini, G.F. (1989) Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thromb. Res., 56, 547-51.
119. Shorr, A.F., Trotta, R.F., Alkins, S.A., Hanzel, G.S. and Diehl, L.F. (1999) D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med., 25, 207-10.
120. Greenberg, C.S., Devine, D.V. and McCrae, K.M. (1987) Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads. Am. J. Clin. Pathol., 87, 94-100.
121. Teitel, J.M., Bauer, K.A., Lau, H.K. and Rosenberg, R.D. (1982) Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood, 59, 1086-97.
122. Bauer, K.A., Kass, B.L., ten Cate, H., Bednarek, M.A., Hawiger, J.J. and Rosenberg, R.D. (1989) Detection of factor X activation in humans. Blood, 74, 2007-15.
123. ten Cate, H., Bauer, K.A., Levi, M., Edgington, T.S., Sublett, R.D., Barzegar, S., et al. (1993) The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J. Clin. Invest., 92, 1207-12.
124. Takahashi, H., Wada, K., Niwano, H. and Shibata, A. (1992) Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul. Fibrinolysis, 3, 813-8.
125. Kario, K., Matsuo, T., Kodama, K., Matsuo, M., Yamamoto, K. and Kobayashi, H. (1992) Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis, 22, 179-86.
126. Bick, R.L. (1996) Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin. Thromb. Hemost., 22, 69-88.
127. Hesselvik, J.F., Blomback, M., Brodin, B. and Maller, R. (1989) Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit. Care Med., 17, 724-33.
128. Fijnvandraat, K., Derkx, B., Peters, M., Bijlmer, R., Sturk, A., Prins, M.H., et al. (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb. Haemost., 73, 15-20.
129. Wuillemin, W.A., Fijnvandraat, K., Derkx, B.H., Peters, M., Vreede, W., ten Cate, H. and Hack, C.E. (1995) Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb. Haemost., 74, 1436-41.
130. Mesters, R.M., Helterbrand, J., Utterback, B.G., Yan, B., Chao, Y.B., Fernandez, et al. (2000) Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care Med., 28, 2209-16.
131. Taylor, F.BJ., Toh, C.H., Hoots, W.K., Wada, H. and Levi, M. (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost., 86, 1327-30.
132. Bakhtiari, K., Meijers, J.C., de Jonge, E. and Levi, M. (2004) Prospective validation of the international society of thrombosis and maemostasis scoring system for disseminated intravascular coagulation. Crit. Care Med., 32, 2416-21.
133. Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B.R., Brandt, J.T., et al. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost., 2, 1924-33.
134. Alving, B.M., Spivak, J.L. and DeLoughery, T.G. (1998) Consultative hematology: Hemostasis and transfusion issues in surgery and critical care medicine. Hematology 1998 (Am. Soc. Hematol. Educ. Program), 320-41.
135. de Jonge, E., Levi, M., Stoutenbeek, C.P. and van Deventer, S.J. (1998) Current drug treatment strategies for disseminated intravascular coagulation. Drugs, 55, 767-77.
136. du Toit, H., Coetzee, A.R. and Chalton, D.O. (1991) Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crit. Care Med., 19, 1195-200.
137. Feinstein, D.I. (1982) Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. (Review; 34 refs). Blood, 60, 284-7.
138. Dorffler-Melly, J., de Jonge, E., Pont, A.C., Meijers, J., Vroom, M.B., Buller, H.R. and Levi, M. (2002) Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet, 359, 849-50.
139. Vlasuk, G.P., Bergum, P.W., Bradbury, A.E., Loynds, P., Mant, T.G. and Rote, W.E. (1997) Clinical evaluation of rNAPc2, an inhibitor of the fVIIa/tissue factor coagulation complex. Am. J. Cardiol., 80, 66S.
140. Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., et al. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med., 29, 2081-9.
141. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290, 238-47.
142. Levi, M., de Jonge, J.E. and Van Der Poll, T. (2001) Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit. Care Med., 29(7 Suppl), S90-S94.
143. Fourrier, F., Chopin, C., Huart, J.J., Runge, I., Caron, C. and Goudemand, J. (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest, 104, 882-8.
144. Eisele, B., Lamy, M., Thijs, L.G., Keinecke, H.O., Schuster, H.P., Matthias, F.R., et al. (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis (see comments). Intensive Care Med., 24, 663-72.
145. Baudo, F., Caimi, T.M., de, C.F., Ravizza, A., Arlati, S., Casella, G., et al. (1998) Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study [see comments]. Intensive Care Med., 24, 336-42.
146. Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., et al. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 286, 1869-78.
147. Bernard, G.R., Ely, E.W., Wright, T.J., Fraiz, J., Stasek, J.E., Jr., Russell J.A., et al. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit. Care. Med., 29, 2051-9.
148. Vincent, J.L., Angus, D.C., Artigas, A., Kalil, A., Basson, B.R., Jamal, H.H., et al. (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit. Care Med., 31, 834-40.